Cohance Lifesciences Limited (BOM:543064)
India
· Delayed Price · Currency is INR 542.20
-6.90 (-1.26%)
At close: Dec 5, 2025
Cohance Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2019 |
| Operating Revenue | 12,106 | 11,976 | 10,514 | 13,403 | 13,202 | 10,097 | Upgrade
|
| Other Revenue | - | - | - | - | - | -0 | Upgrade
|
| Revenue | 12,106 | 11,976 | 10,514 | 13,403 | 13,202 | 10,097 | Upgrade
|
| Revenue Growth (YoY) | 25.95% | 13.91% | -21.56% | 1.52% | 30.75% | 21.10% | Upgrade
|
| Cost of Revenue | 3,374 | 3,757 | 3,716 | 5,882 | 5,741 | 4,372 | Upgrade
|
| Gross Profit | 8,732 | 8,219 | 6,797 | 7,521 | 7,461 | 5,725 | Upgrade
|
| Selling, General & Admin | 3,183 | 2,562 | 1,396 | 1,218 | 1,024 | 784.18 | Upgrade
|
| Research & Development | - | - | - | - | 103.55 | 110.58 | Upgrade
|
| Other Operating Expenses | 2,469 | 1,601 | 1,311 | 561.82 | 526.62 | 415.35 | Upgrade
|
| Operating Expenses | 6,628 | 4,938 | 3,253 | 2,259 | 2,045 | 1,626 | Upgrade
|
| Operating Income | 2,105 | 3,281 | 3,544 | 5,262 | 5,416 | 4,099 | Upgrade
|
| Interest Expense | -114.8 | -123.5 | -74.5 | -128.11 | -62.31 | -91.44 | Upgrade
|
| Interest & Investment Income | 12.7 | 12.7 | 19.3 | 58.32 | 0.69 | 2.68 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 411.12 | 537.36 | Upgrade
|
| Currency Exchange Gain (Loss) | 116.6 | 116.6 | 81.2 | 214.38 | 164.21 | 95.59 | Upgrade
|
| Other Non Operating Income (Expenses) | -45.9 | 12.4 | 66.8 | 32.9 | 0.02 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 2,073 | 3,299 | 3,637 | 5,439 | 5,930 | 4,643 | Upgrade
|
| Merger & Restructuring Charges | -383.6 | -302.6 | -31.1 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 409.6 | 409.6 | 449.1 | 156.87 | 636.14 | 33.28 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.1 | -1.1 | -0.7 | -0.07 | 106.03 | 0.34 | Upgrade
|
| Other Unusual Items | 34.3 | 34.3 | 2.7 | 1.17 | 3.73 | - | Upgrade
|
| Pretax Income | 2,133 | 3,439 | 4,057 | 5,597 | 6,676 | 4,677 | Upgrade
|
| Income Tax Expense | 493.1 | 791.5 | 1,054 | 1,484 | 2,138 | 1,053 | Upgrade
|
| Earnings From Continuing Operations | 1,640 | 2,648 | 3,003 | 4,113 | 4,538 | 3,623 | Upgrade
|
| Minority Interest in Earnings | 130.4 | 31 | - | - | - | - | Upgrade
|
| Net Income | 1,770 | 2,679 | 3,003 | 4,113 | 4,538 | 3,623 | Upgrade
|
| Net Income to Common | 1,770 | 2,679 | 3,003 | 4,113 | 4,538 | 3,623 | Upgrade
|
| Net Income Growth | -27.20% | -10.79% | -26.99% | -9.37% | 25.24% | 14.30% | Upgrade
|
| Shares Outstanding (Basic) | 255 | 255 | 255 | 255 | 255 | 255 | Upgrade
|
| Shares Outstanding (Diluted) | 256 | 256 | 255 | 255 | 255 | 255 | Upgrade
|
| Shares Change (YoY) | 0.56% | 0.49% | - | - | - | - | Upgrade
|
| EPS (Basic) | 6.94 | 10.52 | 11.80 | 16.16 | 17.83 | 14.23 | Upgrade
|
| EPS (Diluted) | 6.88 | 10.45 | 11.80 | 16.16 | 17.83 | 14.23 | Upgrade
|
| EPS Growth | -27.90% | -11.45% | -26.99% | -9.37% | 25.27% | 14.30% | Upgrade
|
| Free Cash Flow | 1,366 | 1,325 | 3,329 | 1,713 | 2,548 | 2,717 | Upgrade
|
| Free Cash Flow Per Share | 5.33 | 5.18 | 13.08 | 6.73 | 10.01 | 10.67 | Upgrade
|
| Dividend Per Share | - | - | - | - | 2.000 | 2.000 | Upgrade
|
| Dividend Growth | - | - | - | - | - | 60.00% | Upgrade
|
| Gross Margin | 72.13% | 68.63% | 64.65% | 56.11% | 56.51% | 56.70% | Upgrade
|
| Operating Margin | 17.39% | 27.40% | 33.71% | 39.26% | 41.02% | 40.59% | Upgrade
|
| Profit Margin | 14.62% | 22.37% | 28.56% | 30.69% | 34.37% | 35.88% | Upgrade
|
| Free Cash Flow Margin | 11.28% | 11.06% | 31.66% | 12.78% | 19.30% | 26.91% | Upgrade
|
| EBITDA | 3,101 | 4,056 | 4,090 | 5,726 | 5,795 | 4,407 | Upgrade
|
| EBITDA Margin | 25.61% | 33.87% | 38.90% | 42.72% | 43.89% | 43.65% | Upgrade
|
| D&A For EBITDA | 995.9 | 774.9 | 546 | 464.6 | 378.64 | 308.36 | Upgrade
|
| EBIT | 2,105 | 3,281 | 3,544 | 5,262 | 5,416 | 4,099 | Upgrade
|
| EBIT Margin | 17.39% | 27.40% | 33.71% | 39.26% | 41.02% | 40.59% | Upgrade
|
| Effective Tax Rate | 23.12% | 23.01% | 25.98% | 26.52% | 32.02% | 22.52% | Upgrade
|
| Revenue as Reported | 12,633 | 12,561 | 11,133 | 13,867 | 14,126 | 10,240 | Upgrade
|
| Advertising Expenses | - | 57.2 | 34.8 | 34.89 | 18.83 | 18.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.